Physician profile
Caitlin Cunningham
NPI 1730531187
$3,770.73
in general payments reported to CMS, 2019-2025
22 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.45 · 2022: $347 · 2023: $786 · 2024: $1,576 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,378.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $591.71 | 2022-2025 | Descovy |
| Viiv Healthcare Company | $525.42 | 2023-2025 | Apretude |
| Pfizer INC. | $512.15 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $366.10 | 2024-2025 | Airsupra, Breztri |
| Abbvie INC. | $307.96 | 2022-2025 | |
| Bausch Health US, LLC | $182.88 | 2022-2025 | Aplenzin, Wellbutrin |
| Otsuka America Pharmaceutical, INC. | $155.92 | 2025 | Rexulti |
| Lilly USA, LLC | $140.92 | 2024-2025 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $125.26 | 2024 | Wavewriter Alpha Prime 16 |
| Astellas Pharma US INC | $121.11 | 2023-2025 | Veozah, Myrbetriq |
| Tris Pharma INC | $116.13 | 2023-2025 | Dyanavel Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $116.00 | 2022 | |
| Lundbeck LLC | $97.57 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $72.62 | 2023 | Qelbree |
| Amgen INC. | $70.00 | 2021-2025 | Krystexxa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $67.29 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Daiichi Sankyo INC. | $65.01 | 2023-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $61.04 | 2022-2024 | Gardasil 9, Gardasil |
| Hologic Sales and Service, LLC | $26.71 | 2024 | Aptima |
| Takeda Pharmaceuticals U.S.A., INC. | $17.98 | 2025 | Trintellix |
| Ars Pharmaceuticals Operations, INC. | $16.41 | 2025 | Neffy |
| Medtronic, INC. | $14.54 | 2025 | Inceptiv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.